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Abstract. Proliferation of some cultured human tumor 
cell lines bearing high numbers of epidermal growth 
factor (EGF) receptors is paradoxically inhibited by 
EGF in nanomolar concentrations. In the present 
study, we have investigated the biochemical mechanism 
of growth inhibition in A431 human squamous carci- 
noma cells exposed to exogenous EGF. In parallel, we 
studied a selected subpopulation, A431-F, which is re- 
sistant to EGF-mediated growth inhibition. We ob- 
served a marked reduction in cyclin-dependent kinase- 
2 (CDK2) activity when A431 and A431-F cells were 
cultured with 20 nM EGF for 4 h. After further contin- 
uous exposure of A431 cells to EGF, the CDK2 activity 
remained at a low level and was accompanied by persis- 
tent G1 arrest. In contrast, the early reduced CDK2 ac- 
tivity and G1 accumulation in A431-F cells was only 
transient. We found that, at early time points (4-8 h), 
EGF induces p21 cipl/wAvl mRNA and protein expres- 
sion in both EGF-sensitive A431 cells and EGF-resis- 
tant A431-F cells. But only in A431 cells, was p21 cipl/wAF1 
expression sustained at a significantly increased level 
for up to 5 d after addition of EGF. Induction of 
p21 cipvwAF1 by EGF could be inhibited by a specific 
EGF receptor tyrosine kinase inhibitor, tyrphostin 
AG1478, suggesting that p21 cipl/wAF1 induction was a 
consequence of receptor tyrosine kinase activation by 
EGF. We also demonstrated that the increased 
p21Cipl/wAF1 was associated with both CDK2 and prolif- 
erating cell nuclear antigen (PCNA). Taken together, 
our results demonstrate that p21Cipl/wAF1 is an impor- 
tant mediator of EGF-induced G1 arrest and growth in- 
hibition in A431 cells. 
PIDERMAL growth factor (EGF) ~ is a potent mitogen 
for most epithelial tissues. Binding of EGF to spe- 
cific cell surface receptors stimulates formation of 
noncovalent homodimers (or oligomers) involving two (or 
more) EGF receptors, which  activates receptor tyrosine 
kinase and results in transphosphorylation of tyrosine resi- 
dues on the opposite member of the pair. The tyrosine au- 
tophosphorylated EGF receptors exhibit increased bind- 
ing affinities for the Src homology 2 regions of substrate 
molecules. Substrate binding to receptors is followed by 
phosphorylation  of the  substrate  molecules  on  tyrosine 
residues, which results in a  cascade of biochemical steps 
involved in the mitogenic signal transduction pathways of 
cells (Carpenter, 1992; Ullrich and Schlessinger, 1990). 
While EGF has a stimulatory effect on the proliferation 
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of a wide variety of normal and malignant cells, the growth 
of some cultured tumor cell lines bearing high levels of 
EGF receptors was found, paradoxically, to be inhibited 
by  exposure  to  exogenous EGF  (Gill  and  Lazar,  1981; 
Barnes, 1982; Kawamoto et al., 1983; Filmus et al., 1985; 
Davidson et al., 1987; Ennis et al., 1989; Gross et aL, 1991). 
The  human  epidermoid  carcinoma  cell  line  A431  ex- 
presses a high number of EGF receptors (~2  x  106/cell) 
and its growth in monolayer culture is inhibited by nano- 
molar concentrations of EGF that are mitogenic to other 
cell lines (Gill and Lazar, 1981; Barnes, 1982; Kawamoto 
et al., 1983; Fan et al., 1993a). EGF also inhibits anchorage 
independent growth of A431 cells in soft agar (Fernandez- 
Pol et al.,  1986).  Growth inhibition by EGF can be modi- 
fied  by  blockade  of  EGF  receptors  with  anti-receptor 
mAb.  The  concentration  of mAb  must  be  carefully ti- 
trated, since total receptor blockade by mAb also inhibits 
cell growth (Sato et al., 1983; Kawamoto et al., 1983, 1984; 
Ennis et al., 1989; Fan et al., 1993a). The biochemical pro- 
cesses  by  which  EGF  inhibits  cell  proliferation remain 
poorly  understood.  Low  (picomolar)  concentrations  of 
EGF can  stimulate  A431  cell growth  in culture  (Kawa- 
moto  et  al.,  1984).  Furthermore,  treatment  of  athymic 
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nografts  (Ginsburg  and  Vonderhaar,  1985),  suggesting 
that EGF-mediated inhibition of proliferation may be re- 
lated to the stimulation of large numbers of receptors in 
cultured cells. 
Recently, studies on the function of cellular proto-onco- 
genes indicate that the products of many of these genes 
play a critical role in cell cycle progression (Hunter, 1991; 
Weinberg, 1991; Hartwell and Kastan, 1994). Mammalian 
cell cycle traversal and cell division are controlled by the 
ordered activation of a group of related serine/threonine 
kinases, known as cyclin-dependent kinases (CDKs). The 
activities of these kinases are regulated by their levels of 
phosphorylation (Gu et al., 1993) and by their periodic as- 
sociation with positive regulatory subunits called cyclins 
(Sherr, 1993).  Orderly progression through the cell cycle 
requires  sequential  formation of different activated  cy- 
clin-CDK complexes at appropriate phases of the mitotic 
cycle.  In  vertebrate  cells,  the  predominant  cyclin-CDK 
complexes required for traversal of the cell cycle are cyclin 
D-CDK4, cyclin E-CDK2, cyclin A-CDK2, and cyclin A~ 
B-CDC2, acting at G1, G1/S, S, and G2/M, respectively 
(Sherr, 1993).  Recently, a new group of negative regula- 
tors of the cell cycle, called CDK inhibitors or CDIs, has 
been  discovered  in  mammalian cells.  Among them  are 
p21Cipl/WAF1 (variously named CDK-interacting protein 1 
[Cipl]\wild-type p53-activated fragment 1 [WAF1]\SDII\ 
CAP20) (E1-Deiry et al., 1993; Gu et al.,  1993; Gyuris et 
al.,  1993; Harper  et  al.,  1993; Xiong  et  al.,  1993) and 
p27 KtP1 (Polyak et  al.,  1994a,b;  Toyoshima and Hunter, 
1994)  that can bind to and inactivate CDK-cyclin com- 
plexes in mammalian cells (Sherr, 1993, 1994). p21 ciplmAFa 
also  binds to proliferating cell nuclear antigen (PCNA) 
and inhibits in vitro PCNA-dependent DNA replication 
(Flores-Rozas et al., 1994; Waga et al., 1994), which p27 KIP1 
cannot do (Luo et al., 1995). It has been reported that the 
CDK and PCNA inhibitory activities of p21Cipl/WAF1  are 
functionally independent. An amino-terminal domain of 
the p21 cipl/wAFt molecule inhibits cyclin/CDK kinases and 
a  carboxy-terminal domain inhibits PCNA  (Chen et al., 
1995; Luo et al., 1995). 
In the present study, we investigated the biochemical 
mechanism by which EGF inhibits cell cycle progression in 
A431 cells. To define the molecular events responsible for 
EGF-induced  growth  inhibition,  we  selected  an  A431 
subpopulation, A431-F, that is resistant to EGF-induced 
growth inhibition. We provide evidence that p21Cipl/wAF1 is 
induced by EGF and mediates EGF-induced cell cycle ar- 
rest and growth inhibition in A431 cells through its associ- 
ation with the cyclin/CDK2 complex and PCNA. 
Materials and Methods 
Reagents 
EGF was obtained from Collaborative Research Inc. (Bedford, MA). An- 
tibodies reactive with human CDK2, CDK4, cyclin E, cyclin A, cyclin D, 
and PCNA were purchased from Santa Cruz Biotechnology Inc. (Santa 
Cruz, CA). Antibody against p21Cipl/wAF1 was from Pharmigen Biotech- 
nology Inc. (San Diego, CA). Antibody against p27  KIm was generated by 
immunizing a rabbit with a mouse p27-GST fusion protein described pre- 
viously (Polyak et al., 1994a). Anti-phosphotyrosine antibody PY69 was 
obtained from ICN Biomedicals Inc.  (Irvine, CA). Tyrphostin AG1478 
was kindly provided by Dr.  Alexander Levitzki (Hebrew  University of 
Jerusalem, Israel)  and was dissolved in absolute DMSO  (Levitzki and 
Gazit, 1995). All other chemicals were ordered from Sigma Chem. Co. (St. 
Louis, MO) unless specified elsewhere. 
Cells and Cell Culture 
A431 human vulvar squamous carcinoma ceils have been described previ- 
ously and are maintained in DMEM/Ham's F12 medium (1:1)  with 0.5% 
fetal bovine serum (Fan et al., 1994).  The A431-F cell subpopulation was 
selected by long-term exposure of A431 cells to a saturating concentration 
of monoclonal antibody (mAb) 225 (50 nM), which blocks receptor acti- 
vation by ligand (Fan et al., 1993a).  After three months of culture, 225 
mAb was removed and cells were allowed to grow in the absence of 225 
mAb. These selected cells have been shown to  express about half the 
number of EGF receptors compared with parental A431 cells, evidenced 
by an 125I-EGF  receptor saturation binding assay, Western blot analysis 
using an antibody against the intracellular domain of the EGF receptor, as 
well as Northern analysis of EGF  receptor mRNA expression. A431-F 
cells proliferate at a reduced rate and also are less sensitive to 225 mAb- 
mediated growth inhibition, compared with parental A431 cells (data not 
shown). 
Cell Proliferation and Flow Cytometry 
The cell proliferation assay was performed in six-well cell culture plates. 
A431 or A431-F cells were cultured with or without 20 nM EGF for 5 d 
with one change of growing medium and addition of EGF on day 3. After 
5 d of culture, cells were harvested by trypsinization and counted with a 
Coulter counter. 
For the flow cytometric analysis of DNA content, cells were cultured 
with or without 20 nM EGF for indicated time periods and then were har- 
vested by trypsinization and fixed with 70% ethanol. Cells were stained 
for DNA by washing and suspending them in 2 ml PBS containing 50 txg 
propidium iodide/106  ceils (Sigma) and 100 ~g/ml RNase I (Sigma) and in- 
cubated for 6 h at room temperature. After filtering cells through 50-70- 
Ixm pore size nylon mesh, cell cycle distribution was analyzed by a FACS- 
can flow cytometer (Becton Dickinson, San Jose, CA). 
Histone HI Kinase Assay 
Cells were treated with EGF for indicated time periods and harvested by 
trypsinization. Cell lysates were prepared by sonication in HKM buffer 
(40 mM Hepes-KOH, pH 7.5, 1 mM MgC12, 0.5 mM dithiothreitol, 2 mM 
phenylmethylsulfonyl fluoride) or 0.5% NP-40 lysis buffer (described be- 
low)  at 4°C. Freshly made and centrifuge-cleared cell  lysates (200  Ixg) 
were subject to immunoprecipitation in 0.5% NP-40 lysis buffer for 1 h at 
4°C in the presence of antibodies against CDK2, cyclin E, cyclin A  or 
p21Cipl/wAF1, followed by another 1-h incubation with immobilized protein 
A-agarose beads  (Repligen  Corp.,  Cambridge,  MA).  The  beads  were 
washed by centrifugation two times with NP-40 lysis buffer and underwent 
four additional washes with kinase assay buffer (20 mM Tris-HCL, pH 7.4, 
7.5 mM MgC12, 1 mM dithiothreitol). Phosphorylation of histone H1 was 
measured by incubating the beads with 50 p.l reaction mixture containing 
30 ~M lithium ATP (Boehringer Mannheim Corp., Indianapolis, IN), 10 
txCi 32p-y-ATP (3,000Ci/mmol; New England Nuclear, Boston, MA), and 
2  p~g histone H1  (Boehringer Mannheim Corp., Indianapolis, IN) in ki- 
nase assay buffer for 30 min at 37°C. The reaction was stopped by boiling 
the sample in Laemmli SDS sample buffer for 5 rain and samples were re- 
solved by 12% SDS-PAGE. The gel was dried and subjected to autoradi- 
ography. Radiolabeled histone H1 bands were quantitated with a  Phos- 
phoimager and analyzed with ImageQuant software (Molecular Dynamics). 
Immunological Analysis (Western Immunoblot 
and Immunoprecipitation) 
Cells were lysed in NP-40 lysis buffer (50 mM Tris-HC1, pH 7.4,  150 mM 
NaC1, 0.5% NP-40, 50 mM NaF, 1 mM Na3VO4,  1 mM phenylmethylsulfo- 
nyl fluoride, 25 p~g/ml leupeptin, and 25 p~g/ml aprotitin) and sonicated at 
4°C. The supernatants were cleared by centrifugation. Protein concentra- 
tions of the lysates were measured by the method of Bradford (Bradford, 
1976).  Equal amounts of protein were subjected to immunoprecipitation 
in the presence of various antibodies by the method previously described 
(Fan et al., 1993b, 1994). For Western immunoblot, equal amounts of pro- 
tein were boiled in Laemmli SDS sample buffer, resolved by SDS-PAGE, 
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Total RNA was prepared from cells by ultracentrifugation of cell homoge- 
nates in guanidine thiocyanate over cushions of cesium chloride. 10 Ixg of 
total RNA was loaded into each well, electrophoretically separated on 1% 
agarose/0.7% formaldehyde gel, and then Northern transferred to nitro- 
cellulose by capillary blot. After baking at 80°C in a vacuum oven for 2 h, 
the blots were prehybridized in 7 mM Tris-HCl buffer, pH 7.4, containing 
5%  dextran  sulfate,  48.5%  formamide,  4X  SSC,  40  jxg/ml  sonicated 
Salmon sperm DNA and 0.Sx Deharts for 2 h at room temperature, fol- 
lowed by overnight hybridization at 42°C with an EcoR I-cut 1.0-kb hu- 
man p21Cip]/wAFt cDNA construct (provided by Dr. Bert Vogelstein at 
Johns Hopkins University, Baltimore, MD) or with an EcoR I-cut 1.4-kb 
housekeeping gene  GAPDH  cDNA.  Probes were  labeled  by random 
primer DNA synthesis according to the manufacturer's instructions (Phar- 
macia Biotech Inc., Uppsala, Sweden). The blots were washed three times 
with 0.1% SDS, 2x  SSC at room temperature, followed by two to three 
washes with 0.1% SDS, 0.1% SSC at 50°C before being subjected to auto- 
radiography. 
Results 
A  B 
Effects of EGF on Cell Proliferation and Cell Cycle 
Arrest in A431 and A431-F Cells 
We have shown previously that proliferation of A431 cells 
was inhibited by addition of nanomolar concentrations of 
EGF (Fan et al., 1993a; Kawamoto et al., 1983; Sato et al., 
1983). To investigate the mechanisms by which EGF in- 
duces this growth inhibition, we derived an A431 cell sub- 
population that was resistant to EGF-induced growth inhi- 
bition (see Materials and Methods). The A431 and A431-F 
cells were  used for comparative studies  of the  effect of 
EGF  upon  sensitive  and  resistant  cells  with  the  same 
genetic  backgrounds.  Stimulation  with  exogenous  EGF 
could activate the A431-F cell EGF receptor tyrosine ki- 
nase,  assayed by receptor tyrosine autophosphorylation, 
suggesting the presence of functional EGF receptor kinase 
in these cells (data not shown). However, unlike the pa- 
rental A431 cells, A431-F cells were found to be resistant 
to EGF-induced growth inhibition during 5 d of cell cul- 
ture (Fig. 1 A). FACS analysis indicated that shortly after 
treatment with 20 nM EGF (9 h), both A431 and A431-F 
cells  arrested  in  G1  phase.  However, during  prolonged 
EGF treatment  (36 h), A431-F cells were released from 
G1  block while the parental A431  cells remained in G1 
block, resulting in reduced entry into G2/M phase (Fig. 1 B). 
Inhibition of CDK2 Activity Accompanies EGF-induced 
Cell Cycle Arrest 
The transition from G1 into S phase in eukaryotic cells is 
governed by the  activation of CDK2. We compared the 
expression and activities of CDK2 and its cyclin partners, 
cyclins E and A, in cultured A431 and A431-F cells treated 
with  EGF.  Fig.  2  A  demonstrates  that  the  activity  of 
CDK2,  assayed by in vitro histone H1  phosphorylation, 
was markedly inhibited without changing the amount of 
CDK2  protein  (Fig.  3 A)  after both type  of cells  were 
treated with EGF for 4-8 h. The suppression of CDK2 ac- 
tivity was sustained in A431 cells. In contrast, in A431-F 
cells, we observed only a transient inhibition of CDK2 ac- 
tivity (Figs. 2 A  and 6 B). These results were consistent 
with FACS analysis data (Fig. 1 B) showing that EGF in- 
duces persistent G1 arrest in A431 cells, but only tempo- 
rarily blocks G1 phase in A431-F cells. 
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Figure 1.  Effects of EGF on cell proliferation and cell cycle distribution in A431 and A431-F cells. (A) A431 (A) and A431-F (0) cells 
were grown in six-well culture plates at 37°C in the presence of indicated concentrations of EGF. The medium and added EGF were re- 
plenished on day 3. Cell numbers were assayed with a  Coulter counter after 5 d of culture and are expressed as the means of triplicates 
with SD (the SD is smaller than the symbol when not shown). The initial cell numbers for A431  and A431-F cells were 2.8  ×  104/well 
and 3.4  ×  10a/well in the respective cultures. (B) Exponentially growing A431  (top row) and A431-F (bottom row) cells were treated 
with 20 nM EGF for 0, 9, or 36 h at 37°C, and their cell cycle distribution was analyzed by flow cytometric analysis of DNA content after 
staining with propidium iodide. 
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Figure  2.  Effects  of  EGF  on 
the histone H1 kinase activities 
of CDK2,  and cyclin E- or cy- 
clin  A-associated  kinase  in 
A431  and  A431-F  cells.  Cells 
were cultured in 20 nM EGF at 
37°C for the indicated time pe- 
riods,  and  then  were  har- 
vested  and  sonicated.  CDK2 
or cyclin E- or cyclin A-associ- 
ated  histone HI  kinase  activi- 
ties were  assayed by immuno- 
precipitation  of  cell  extracts 
with antibodies against human 
CDK2,  cyclin  E  or  cyclin  A, 
followed by incubating the im- 
munoprecipitated beads with a 
reaction  solution  for  the  in 
vitro  phosphorylation  of  his- 
tone H1  as described in Mate- 
rials  and  Methods.  Radiola- 
beled  histone  H1  bands  were separated  by 12%  SDS-polyacrylamide gel  electrophoresis,  quantitated  with  a  Phosphoimager and 
analyzed with ImageQuant software.  The data are plotted in bar graphs. 
It has  been well-documented  that  CDK2  regulates  the 
G1  to  S  phase  transition  through  the  formation  of com- 
plexes with cyclin E  and cyclin A. Therefore, we assayed 
the cyclin E- and cyclin A-associated historic H1 kinase ac- 
tivities  after EGF treatment.  The  cyclin E-associated  ki- 
nase assay on lysates of A431 and A431-F cells revealed an 
early marked inhibition after 4-8 h of EGF treatment, sim- 
ilar to that seen in the direct assays of CDK2 activity (Fig. 
2  B).  However,  after  further  treatment  of A431-F  cells 
with EGF, the cyclin E-associated histone H1 activity rose 
to higher than the original levels (Fig. 2 B). This probably 
was due to the transient,  partial  A431-F cell synchroniza- 
tion in late  G1 phase induced by EGF, resulting in accu- 
mulation of cyclin E  (Fig. 3 B). 
The cyclin A-associated histone H1 kinase activity also 
was inhibited by EGF in A431 cells, although less marked 
than  CDK2  kinase  activity or cyclin E-associated  kinase 
activity (Fig. 2 C). In A431-F cells treated with EGF, inhi- 
bition of cyclin A-associated kinase activity was also tran- 
sient.  It should be noted that cyclin A  can associate with 
both CDK2 and CDC2, and that both of these complexes 
can phosphorylate histone H1. 
EGF  treatment  did  not  change  the  amount  of either 
CDK2 or CDK4 protein (Fig. 3 A), but was accompanied 
by fluctuations in the amount of cyclins that did not corre- 
late  with  the reduction in  CDK2  activity.  Cyclin E  accu- 
mulated  steadily in A431  cells, starting ~24 h  after EGF 
treatment,  but  accumulation  of cyclin E  in  A431-F cells 
was only temporary, declining after further treatment (Fig. 
3  B).  Since  cyclin  E  protein  accumulated  during  EGF 
treatment,  other mechanisms must be invoked to explain 
the inhibition of cyclin E-associated CDK2 kinase activity 
in A431 cells and A431-F cells after short term EGF treat- 
ment, and the loss of this inhibition  in A431-F cells after 
treatment for 24 h with EGF. In A431 cells, cyclin A  levels 
showed no significant change until a late time point (48 h), 
when there was a reduction that could not explain the ear- 
lier fall in CDK2 activity. In A431-F cells, cyclin A  content 
remained unchanged (Fig. 3 B). 
Cyclin D3, which is expressed  in A431  cells,  showed a 
modest increase  after 4 h  treatment with EGF and subse- 
quently returned  to the original levels in both A431  and 
A431-F cells (Fig. 3 B). At no time did it decrease. 
Taken together, these observations suggest that cell cy- 
cle arrest and prolonged inhibition of CDK2 activity were 
not explained by changes in the protein levels of either cy- 
clins or cyclin-dependent kinases in A431 cells. Therefore, 
we explored whether CDK2 inhibitor(s)  were involved in 
EGF-induced cell cycle arrest in these cells. 
Induction of the p21Cipl/WAvl Cell Cycle Inhibitor by 
EGF Treatment in A431 and A431-F Cells 
We  examined  whether  EGF  treatment  can  regulate  ex- 
Figure  3.  Expression of CDKs and cyclins in A431  and A431-F 
cells after EGF treatment. Cells were cultured in 20 nM EGF at 
37°C for the indicated time periods. Cells were lysed as described 
in Materials  and Methods  and boiled in Laemmli SDS sample 
buffer. Equal amounts of protein were loaded onto (A) 15%  or 
(B) 12% SDS-polyacrylamide gels and resolved by electrophore- 
sis. Western immunoblot analyses were performed with antibod- 
ies directed against human CDK2, CDK4, cyclin E, cyclin A, or 
cyclin D3, using ~25I-protein A as label 
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basal  expression  of p21Cipl/wAF1 mRNA  was  very low in 
both A431 and A431-F cells and could be strongly induced 
after 1-2 h  of EGF treatment.  However the expression of 
p21 cipl/wAF1 mRNA  was  reduced  in  A431-F  cells  com- 
pared  with  A431  cells  after  >24  h  of  treatment.  The 
amount  of p21Cipl/wAF1 protein  increased  after  2-h  EGF 
treatment,  in parallel  with  the  expression  of p21Cipl/wAF1 
mRNA.  This  was coincident  with  the  observed  early G1 
cell  cycle arrest  and  inhibition  of CDK2  activity in  both 
A431  and  A431-F  cells  (Fig.  2).  p21Cipl/wgF1 protein 
reached  a  peak in A431  cells  after 4-8 h  EGF treatment 
and decreased modestly afterwards,  but remained  at ele- 
vated levels over a 5-d period of treatment with EGF (Fig. 
4 B). In A431-F cells, the rise in p21Cipl/wAF1 protein levels 
after 4-8 h of treatment with EGF was followed by a sharp 
decline at time points beyond 8 h (Fig. 4). 
We also explored whether p27  KIm could be involved in 
the sustained inhibition of CDK2 activity in parental A431 
cells  exposed  to EGF  treatment.  We  observed  the  pres- 
ence of p27  ~Im in A431  and A431-F cells,  but no signifi- 
cant increases in the content of p27  KIm protein or p27KtP1/ 
CDKs  complexes  were  found during  the  period  of EGF 
treatment, even after 5 d (data not shown). 
Inhibition of EGF-induced p21 Cipl/WAF1 by Tyrphostin, 
an EGF Receptor Tyrosine Kinase Inhibitor 
To confirm the causal role of EGF receptor activation in 
the induction of p21Cipl/wAF1, we employed an EGF recep- 
tor tyrosine kinase inhibitor, tyrphostin AG1478, to exam- 
ine  its  effect  on levels  of EGF-induced  p21  ciplr~vAF1 pro- 
tein.  Fig.  5  A  shows  that  preincubation  of  cells  with 
tyrphostin AG1478 caused a dose-dependent inhibition of 
tyrosine  phosphorylation  on  A431  cell  proteins  induced 
during a 4-h incubation with EGF. In Fig. 5 B, parallel cell 
lysates were examined for p2l Cipl/wAF1 protein expression, 
and it was observed that induction of p21Cipl/wAF1 also was 
inhibited  by AG1478.  The  prevention  of the  EGF-medi- 
ated increase in p21 cipl/wArl expression by a specific inhib- 
itor of EGF receptor tyrosine kinase strongly suggests the 
observed induction  of p21Cipl/wAF1 was a  consequence  of 
EGF receptor activation by ligand. 
Association of  p21 Cipl/wAF1 with CyclinlCDK2 Complex 
To  further  explore  whether  the  observed  inhibition  of 
CDK2 activity was attributable  to the physical association 
of  p21Cipl/wAvl  with  CDK2-cyclins,  we  immunoprecipi- 
tared  the  p21Cipl/wAF1 from lysates  of cells  either  treated 
with EGF or left untreated for periods of 5 h  and 5 d, and 
then  immunoblotted  the  electrophoretically  separated 
Figure 4.  Induction of p2l Cipl/wAF1 mRNA and protein expres- 
sion by EGF in A431 and A431-F cells. Cells were treated with 20 
nM EGF at 37°C for the indicated  time  periods.  Lysates were 
prepared for RNA assays and protein assays as described in Ma- 
terials  and Methods. (A) 10 p~g total RNA in each lane was sepa- 
rated by 1% agarose/0.7% formaldehyde gel electrophoresis. The 
expression of p21 cipl/wAF1 mRNA was assayed by Northern blot 
hybridization with human p21  cipl/wAF1  cDNA fragment, as well as 
a  cDNA fragment of human house  keeping  gene  GAPDH to 
show the  quantitation  of loaded  RNA.  (B)  The  expression  of 
p21Cipa/wAF1 protein was assayed by resolving lysates containing 
equal amounts of protein by electrophoresis, followed by trans- 
ferring samples to nitrocellulose and immunoblotting blots with a 
rabbit anti-p21 cipl/wAF1  antibody, using az5I-protein A as label. 
Figure 5.  Effect of tyrphostin on EGF-induced  of p21Cipl/wAF1 
protein expression.  A431 cells were pretreated with 0, 50, or 150 
nM tyrphostin AG1478 in an equal amount of DMSO (final con- 
centration 0.5%) for 2 h at 37°C, followed by further 4 h incuba- 
tion with or without 20 nM EGF as indicated. Cell lysates were 
prepared and boiled in Laemmli SDS buffer. Equal amounts of 
protein were loaded onto (A) 10%  or (B)  12%  SDS-polyacryl- 
amide gels and resolved by electrophoresis. Western immunoblot 
analyses  were  performed  with  antibodies  directed  against  (A) 
phosphotyrosine (PY), or (B) p21Cip~/wAF1. 
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body. Fig. 6 reveals that CDK2 was coimmunoprecipitated 
by anti-p21 cipl/wAF1 antibody, indicating their in vivo asso- 
ciation. Increased amounts of p21Cipl/WAF1/CDK2 complex 
were found after A431 and A431-F cells were treated for 5 
h with EGF (Fig. 6 A). During further incubation of both 
cell types, the association of CDK2 with p21  cipl/wAF1 (Fig. 
6  A)  parallelled  expression  of p21Cipl/wAFl mRNA  and 
protein (Fig. 4), with a far greater reduction in the A431-F 
cells that  displayed  a  return  of CDK2 kinase  activity to 
high levels (Figs. 2 A  and 6 B). 
In A431-F cells, in which EGF did not inhibit prolifera- 
tion  and  cells  traversed  the  cell  cycle  after  a  transient 
block  in  G1  phase,  p21Cipl/wgF1/CDK2  complexes  de- 
creased  (Fig.  6  A)  and  the  activity of cyclin/CDK2  was 
largely restored (Figs. 2 A  and 6 B). However, the small 
amount of CDK2 that remained associated with p21Cipl/wAF1 
(Fig. 6 A) was not active (Fig. 6 B). In A431 cells, in which 
activation of EGF receptors by ligand persistently inhib- 
ited  cell  cycle  traversal,  the  complexing  of  CDK2  with 
p21Cipl/wAF1 was maintained at high levels (Fig. 6 A) with 
inactivation of the bound CDK2 (Fig. 6 B). This resulted 
in a  sustained reduction  of CDK2 kinase activity (Figs. 2 
and 6 B), which maintained G1 phase arrest of the cell cy- 
cle (Fig. 1) in the EGF treated A431 cells. 
At  the  early  time  points  after  EGF  treatment,  the 
p21Cipl/WAF1/CDK4 complex  was  also  increased  in  both 
A431  and A431-F cells, but the amounts of this complex 
decreased in both cell types after further treatment with 
EGF  (data  not  shown),  suggesting that  the  p21Cipl/WAF1/ 
CDK2 complex is more important than  the  p21Cipl/WAF1/ 
CDK4  complex  in  EGF-mediated  growth  inhibition  of 
A431 cells. 
Association  of  p21 Cipl/WAFI with Proliferating  Cell 
Nuclear Antigen (PCNA) 
Since it has been reported that p21Cipl/wAF1 also binds to 
Figure 6.  Association  of CDK2 with p21Cipl/WAF1 and the associ- 
ated histone  H1 kinase  activity. Cells were treated with 20 nM 
EGF at 37°C for indicated  time periods.  (A) Equal amounts of 
A431 and A431-F cell lysates were subjected  to the immunopre- 
cipitation  with rabbit anti-p21 cipl/wAF1, or with rabbit anti-mouse 
IgG antibody (for nonspecific immunoprecipitation).  The immu- 
noprecipitates were boiled  in Laemmli SDS buffer and loaded 
onto 15%  SDS-polyacrylamide gels. After electrophoresis,  the 
samples were transferred to nitrocellulose,  followed by Western 
immunoblot analysis with  anti-CDK2 antibody.  (B) CDK2 his- 
tone H1 kinase activity and p21CipVWAVl-associated  histone H1 ki- 
nase  activity  were  assayed  by  immunoprecipitation  of  equal 
amounts of A431 and A431-F cell lysates with antibodies against 
CDK2 or  p21Cipl/wAF1, followed  by incubating  the immunopre- 
cipitated  beads with a reaction solution for the in vitro phospho- 
rylation of histone  H1  as described  in Materials  and Methods. 
Radiolabeled histone  H1  bands were separated by 12%  SDS- 
polyacrylamide gel electrophoresis. 
PCNA and inhibits in vitro PCNA-dependent DNA repli- 
cation (Waga et al., 1994; Flores-Rozas et al., 1994;  Chen 
et  al.,  1995),  we  investigated  whether  the  increased 
p21Cipl/wAF1 in EGF-treated A431 cells was also associated 
with PCNA. No significant changes of PCNA levels were 
found in both A431 and A431-F cells incubated with EGF 
for 5 d (Fig. 7 A). However, the increased p21Cipl/wAF1 lev- 
els in EGF-treated A431 cells (Fig. 7 B) was accompanied 
by increased association with PCNA (Fig. 7 C). In A431-F 
cells,  the  rise  and  subsequent  fall  in  p21Cipl/wAF1 levels 
(Fig. 7 B) was accompanied by a rise and fall in p21Cipl/wgF1 
associated PCNA (Fig. 7 C). 
Discussion 
The human A431 squamous carcinoma cell line is unusual 
in that physiologic concentrations of EGF inhibit prolifer- 
ation in culture (Gill and Lazar, 1981; Barnes, 1982; Kawa- 
moto et al., 1983).  In the presence of 5-20 nM exogenous 
EGF, the proliferation of cultured A431 cells is decreased 
by 80% compared to untreated cells. We have shown pre- 
viously that  EGF activates two  regulatory sites in  A431 
cell cycle traversal. The most prominent block was in G1 
phase, preventing entry into S phase, and the other block 
was in G2 phase, inhibiting entry into mitosis (MacLeod et 
al.,  1986).  In mammalian cells, CDKs associated with cy- 
clins D, E, and A  have been implicated in the control of 
G1 to S phase transition. In the present study, we observed 
that  EGF-induced  cell cycle arrest was  accompanied by 
marked inhibition of CDK2 activity, suggesting that CDK2 
is the downstream target of the biological effect of EGF in 
arresting cell cycle traversal. Analysis of cyclin E- and cy- 
clin  A-associated  kinase  activities  further  demonstrated 
that  CDK2  inhibition  can  account  for  the  observed  G1 
block in A431 cells. A431-F cells, which exhibit resistance 
to EGF-induced inhibition of growth, showed a  transient 
and rapidly reversible inhibition of CDK2 activity. 
Cyclin levels have been shown to be rate-limiting factors 
for G1 progression in mammalian cells and many studies 
show that synthesis of cyclins, especial D  type cyclins, may 
be the target of physiological signals that control cell pro- 
Figure  7.  Effect  of  EGF  on 
the  expression  of  PCNA 
protein  and  its  association 
with p21 cipl/wAvl. A431 and 
A431-F  cells were  treated 
with 20 nM EGF at 37°C for 
the indicated time periods. (A) 
The expression of PCNA was 
measured  by loading  cell ly- 
sates  containing  equal 
amounts of protein onto 12% 
SDS-polyacrylamide gels, fol- 
lowed by electrophoresis  and 
Western  immunoblot  analysis 
with  a  monoclonal  antibody 
directed against human PCNA. In B and C, cell lysates were first 
subjected to the immunoprecipitation with rabbit anti-p21  cipl/wAF1 
antibody. The immunoprecipitates  were  boiled in Laemmli  SDS 
buffer, split into two equal parts, loaded onto (B) 13.5% or (C) 12% 
SDS-polyacrylamide gels, and resolved by electrophoresis. Western 
blot analyses were then performed with antibodies directed against 
human (B) p21Cipl/wgF1 or (C) PCNA. 
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subo and  Roberts,  1993;  Quelle  et al.,  1993;  Won  et al., 
1992). Therefore, we explored whether the observed inhi- 
bition of CDK2 could be attributed to reduced cyclin ex- 
pression. Interestingly, we found that the cyclin D3, which 
is the predominant D  cyclin expressed in A431 cells, was 
slightly  increased  after  4-h  incubation  with  exogenous 
EGF and returned to baseline levels after 48 h of culture 
with EGF. Similar changes in cyclin D3 levels were found 
in EGF-resistant A431-F cells. Cyclin E levels were persis- 
tently increased for up to 48 h in A431 cells cultured with 
EGF. In contrast, A431-F cells treated with EGF showed a 
temporary increase of cyclin E  followed by a  decline  to- 
wards  baseline  levels,  as  the  cells were  released  from a 
transient G1 arrest. Since cyclin E is synthesized starting in 
late G1 phase, the differences between A431 and A431-F 
cells in their responses to EGF could be explained by per- 
sistent G1 arrest in A431 cells and only temporary G1 ar- 
rest in A431-F cells. The expression of cyclin A  was re- 
duced in A431 cells after 48 h incubation with EGF but no 
significant change of cyclin A  was found in A431-F cells. 
Cyclin A is synthesized primarily during S phase of the cell 
cycle and  the  reduced  percent  of S  phase cells  in  A431 
cells arrested in G1 by EGF treatment may explain the re- 
duced  levels of cyclin A  observed in these cultures.  The 
levels  of  the  three  cyclins  never  reached  values  below 
those observed prior to treatment of cultures with EGF. 
Taken together, these observations suggest that changes in 
the expression of cyclins after EGF treatment are the con- 
sequence, rather than the cause, of the reduced CDK2 ac- 
tivity induced by EGF. 
Recent research from a number of laboratories suggests 
that p21 cip~/wAF1 is a universal inhibitor of cyclin-dependent 
kinase. The catalytic activity of each member of the cyclin- 
dependent kinase family can be inhibited by p21Cipl/wAF1, 
although  their  relative  affinities  vary with  each  enzyme 
(Xiong et al.,  1993;  Gu et al.,  1993;  Harper et al.,  1993). 
The regulation of p21Cipl/wAF1  under different physiologi- 
cal situations may be through p53-dependent or p53-inde- 
pendent pathways. For example, when cell DNA is dam- 
aged by ~/-radiation or chemotherapeutic agents, p21  cipl/wAF1 
may be induced through the p53-dependent pathway (E1- 
Deiry et al., 1993; Xiong et al., 1993; Johnson et al., 1994). 
Cells with damaged DNA that have a normal p53 gene will 
undergo G1 arrest before the initiation of DNA synthesis; 
if cells can pass the G1 checkpoint because of an abnormal 
p53  gene,  they  may become  apoptotic  (E1-Deiry  et  al., 
1994).  When resting cell cultures are stimulated by mito- 
gens, such as growth factors or serum, or when cells are 
undergoing  differentiation,  a  p53-independent  transient 
induction  of increased  p21 cipl/wAF1  may  occur,  and  this 
temporary elevation has been postulated to serve as an in- 
ternal control mechanism, preventing the cells from enter- 
ing S phase prematurely (Harper et al.,  1993;  Michieli et 
al., 1994; MacLeod et al., 1995; Parker et al., 1995).  In the 
present study, we found that, as an early response to EGF 
treatment for 4-8 h,  p21 cipl/WAF1 is markedly induced  in 
both EGF-sensitive A431 and EGF-resistant A431-F cells. 
This corresponds to the timing of G1 arrest on the flow cy- 
tometry analysis of both cell types (Fig. 1). The changes in 
p21 cipl/wAF1 expression appear to be independent  of p53, 
since  this  gene  is  mutated  in  A431  cells  (Kowk  et  al., 
1994).  Our  data  fit  the  model  that  p21Cipl/wAF1 levels 
present a threshold that cyclin-CDK complexes must over- 
come before the cell can enter into S phase (Xiong et al., 
1993; Zhang et al., 1994). At early time points after expo- 
sure of both A431 and A431-F cells to EGF, p21 Cipl/wAF1 is 
induced and causes growth arrest by functioning to inhibit 
the  activity of the  cyclin/CDK2 complex (Figs.  2  and 6) 
and as noted above, this could serve as an internal control 
mechanism (cell cycle brake) to prevent the cells from en- 
tering  S  phase  prematurely.  In  the  EGF-sensitive  A431 
cells, p21 Cipl/wAFI remains persistently upregulated at high 
levels and associates with and inhibits cyclin/CDK2 for up 
to 5 d of incubation (Fig. 6), while in the A431-F cells the 
reduction of p21cipvWAF1/CDK2 complex permits cell cycle 
traversal and cell proliferation. 
We also have demonstrated that EGF-induced p21 cipl/wAF1 
is associated with PCNA, a protein essential for DNA rep- 
lication. This provides a second mechanism, by which ele- 
vated p21 Cipl/wAF1 may act to inhibit cell cycle traversal in 
EGF-treated A431 cells. 
Preliminary data from our laboratory and  others have 
demonstrated  induction  of p21 cipl/wAF1 by EGF in  DiFi 
colon  adenocarcinoma  cells  (unpublished  observation), 
MDA468 human breast adenocarcinoma cells (Jiang, A., 
T. J. Thomas, C. A. Faaland, and T. Thomas. 1995. Proc. 
Am. Assoc.  Cancer Res. 36:580.)  and ME180 human cervi- 
cal  squamous  carcinoma cells  (Brown,  C.,  M.  Rubin,  T. 
DeBlasio, H. Masui, and J. Mendelsohn.  1995. Proc. Am. 
Assoc.  Cancer Res. 36:34).  Each of these cell lines is inhib- 
ited by nanomolar concentrations of exogenous EGF. We 
conclude that p21Cipl/wAvl is involved in the general mech- 
anism of EGF-induced growth inhibition,  although other 
unknown regulatory molecules could also play important 
roles. 
Several hypotheses have been proposed to explain the 
possible mechanisms by which EGF inhibits the growth of 
malignant cell lines expressing high numbers of receptors. 
These  include  EGF effects on the  organization  of cyto- 
skeletal  elements  that  regulate  mitotic  events  (Barnes, 
1982);  the energy expenditure necessary for phosphoryla- 
tion, internalization, degradation and synthesis of a large 
numbers of receptors (Kaplan et al., 1990);  and prolonged 
phosphorylation of lipocortin-1 (Karasik et al., 1990).  Our 
demonstration  that  sustained  elevation of p21 Cipl/WAF1 is 
important in mediation of EGF-induced A431 cell inhibi- 
tion provides a focus for further mechanistic studies of this 
"paradoxical" response, as well as further studies  of the 
control of cell cycle progression by growth factors. We are 
currently pursuing the  causal  relationship  between  EGF 
receptor activation and selective p21 Cipl/wAF1 induction in 
studies of downstream substrates of the EGF receptor ty- 
rosine kinase, and in studies of EGF-mediated activation 
of the promoter for the p21 cipi/wAvl gene and changes in 
synthesis and catabolism of p21 cipvwAF1. 
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